Quratis Inc. (KOSDAQ:348080)

Market Cap	92.47B +89.7%
Revenue (ttm)	2.46B +557.3%
Net Income	-29.67B
EPS	-412.00
Shares Out	105.56M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	242,482
Average Volume	510,715
Open	945.00
Previous Close	940.00
Day's Range	900.00 - 964.00
52-Week Range	612.00 - 2,095.00
Beta	-0.19
RSI	41.38
Earnings Date	n/a

About Quratis

Quratis Inc. engages in developing vaccines in South Korea. It is involved in developing QTP101, a vaccine for tuberculosis; QTP104, a next-generation mRNA vaccine; CPP (Cell Penetrating Peptide) Platform, a cell and bacterial penetration peptide drug delivery platform technology; and Peptide Nucleic Acid (PNA), a synthetic analogue of DNA in which the deoxyribose phosphate backbone. The company also offers drugs contract development and manufacturing services. Quratis Inc. was incorporated in 2016 and is based in Cheongju-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 348080

Financial Performance

In 2025, Quratis's revenue was 2.46 billion, an increase of 557.29% compared to the previous year's 373.80 million. Losses were -29.67 billion, 13.0% more than in 2024.